UK Markets close in 6 hrs 41 mins

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.6200-0.0220 (-3.42%)
At close: 04:00PM EST
0.6390 +0.02 (+3.06%)
After hours: 05:27PM EST

AgeX Therapeutics, Inc.

1101 Marina Village Parkway
Suite 201
Alameda, CA 94501
United States
510 671 8370
http://www.agexinc.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees6

Key executives

NameTitlePayExercisedYear born
Dr. Michael D. WestFounder, Pres, CEO & Director561.03kN/A1953
Ms. Eun-Jae Park CPAChief Financial Officer277.35kN/A1972
Dr. Nafees Naseer Malik M.D.Chief Operating Officer282.27kN/A1978
Dr. Ivan LabatChief Information OfficerN/AN/AN/A
Ms. Judith SegallSec.N/AN/A1953
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.

Corporate governance

AgeX Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.